Home > Publications database > Combined BNCT-CIRT treatment planning for glioblastoma using the effect-based optimization. > print

001     286649
005     20240301121551.0
024 7 _ |a 10.1088/1361-6560/ad120f
|2 doi
024 7 _ |a pmid:38048635
|2 pmid
024 7 _ |a 0031-9155
|2 ISSN
024 7 _ |a 1361-6560
|2 ISSN
037 _ _ |a DKFZ-2024-00017
041 _ _ |a English
082 _ _ |a 530
100 1 _ |a Han, Yang
|b 0
245 _ _ |a Combined BNCT-CIRT treatment planning for glioblastoma using the effect-based optimization.
260 _ _ |a Bristol
|c 2024
|b IOP Publ.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1704291114_22363
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Objective. Boron neutron capture therapy (BNCT) and carbon ion radiotherapy (CIRT) are emerging treatment modalities for glioblastoma. In this study, we investigated the methodology and feasibility to combine BNCT and CIRT treatments. The combined treatment plan illustrated how the synergistic utilization of BNCT's biological targeting and CIRT's intensity modulation capabilities could lead to optimized treatment outcomes.Approach. The Monte Carlo toolkit, TOPAS, was employed to calculate the dose distribution for BNCT, while matRad was utilized for the optimization of CIRT. The biological effect-based approach, instead of the dose-based approach, was adopted to develop the combined BNCT-CIRT treatment plans for six patients diagnosed with glioblastoma, considering the different radiosensitivity and fraction. Five optional combined treatment plans with specific BNCT effect proportions for each patient were evaluated to identify the optimal treatment that minimizes damage on normal tissue.Main results. Individual BNCT exhibits a significant effect gradient along with the beam direction in the large tumor, while combined BNCT-CIRT treatments can achieve uniform effect delivery within the clinical target volume (CTV) through the effect filling with reversed gradient by the CIRT part. In addition, the increasing BNCT effect proportion in combined treatments can reduce damage in the normal brain tissue near the CTV. Besides, the combined treatments effectively minimize damage to the skin compared to individual BNCT treatments.Significance. The initial endeavor to combine BNCT and CIRT treatment plans is achieved by the effect-based optimization. The observed advantages of the combined treatment suggest its potential applicability for tumors characterized by pleomorphic, infiltrative, radioresistant and voluminous features.
536 _ _ |a 315 - Bildgebung und Radioonkologie (POF4-315)
|0 G:(DE-HGF)POF4-315
|c POF4-315
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a boron neutron capture therapy
|2 Other
650 _ 7 |a carbon ion radiotherapy
|2 Other
650 _ 7 |a combined treatment
|2 Other
650 _ 7 |a effect-based optimization
|2 Other
650 _ 7 |a glioblastoma
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Glioblastoma: radiotherapy
|2 MeSH
650 _ 2 |a Boron Neutron Capture Therapy: methods
|2 MeSH
650 _ 2 |a Brain
|2 MeSH
650 _ 2 |a Radiotherapy Dosage
|2 MeSH
650 _ 2 |a Heavy Ion Radiotherapy
|2 MeSH
700 1 _ |a Geng, Changran
|0 0000-0002-6332-6193
|b 1
700 1 _ |a Altieri, Saverio
|0 0000-0002-1376-3686
|b 2
700 1 _ |a Bortolussi, Silva
|0 0000-0003-0452-2255
|b 3
700 1 _ |a Liu, Yuanhao
|b 4
700 1 _ |a Wahl, Niklas
|0 P:(DE-He78)dfd5aaf608015baaaed0a15b473f1336
|b 5
|u dkfz
700 1 _ |a Tang, Xiaobin
|0 0000-0003-3308-0468
|b 6
773 _ _ |a 10.1088/1361-6560/ad120f
|g Vol. 69, no. 1, p. 015024 -
|0 PERI:(DE-600)1473501-5
|n 1
|p 015024
|t Physics in medicine and biology
|v 69
|y 2024
|x 0031-9155
909 C O |o oai:inrepo02.dkfz.de:286649
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)dfd5aaf608015baaaed0a15b473f1336
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-315
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Bildgebung und Radioonkologie
|x 0
914 1 _ |y 2024
915 _ _ |a National-Konsortium
|0 StatID:(DE-HGF)0430
|2 StatID
|d 2023-08-26
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-08-26
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-26
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b PHYS MED BIOL : 2022
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-08-26
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-08-26
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-08-26
920 1 _ |0 I:(DE-He78)E040-20160331
|k E040
|l E040 Med. Physik in der Strahlentherapie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)E040-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21